PRKAA2 and prostate carcinoma: UBE2O inhibits myeloma tumor growth, while it promotes tumorigenesis in breast cancer and prostate cancer by degradation of AMPKα2 and facilitated lung cancer progression by degradation of Mix1 [36, 48].